Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TRIM15 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9C019 |
|---|---|
| Clone Names | 100408308 |
| Gene ID | 89870 |
|---|---|
| Other Names | Tripartite motif-containing protein 15, RING finger protein 93, Zinc finger protein 178, Zinc finger protein B7, TRIM15, RNF93, ZNF178, ZNFB7 |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13640c was selected from the Center region of TRIM15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | TRIM15 |
|---|---|
| Synonyms | RNF93, ZNF178, ZNFB7 |
| Function | E3 ubiquitin ligase that plays a role in several processes including innate antiviral immnity, cell migration and chemotaxis (PubMed:34142270, PubMed:23077300). Acts as a 'Lys-63'-specific ubiquitin ligase for MAPK1/ERK2 and MAPK3/ERK1, promoting their activation by facilitating their interaction with MAP2K1 and MAP2K2 (PubMed:34497368). Plays also a role in cell migration and chemotaxis by acting as a stable focal adhesion component upon recruitment by multi-adapter protein paxillin/PXN (PubMed:25015296). Functions in the RIGI-mediated interferon induction pathway upstream or at the level of MAVS (PubMed:23077300). Inhibits NF-kappa-B activation by turnover of 'Lys-63'-linked ubiquitination of MAP3K7/TAK1. Mechanistically, prevents TRIM8 cytoplasmic translocation and thus inhibits TRIM8- mediated 'Lys-63'-linked polyubiquitination of MAP3K7/TAK1 in the cytoplasm (PubMed:34871740). Plays also an important regulatory effect on the activation of hepatic stellate cells (HSCs). |
| Cellular Location | Cytoplasm. Nucleus Cell junction, focal adhesion Note=Localizes to focal adhesions during the early stage of adhesion biogenesis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of thetripartite motif (TRIM) family. The TRIM motif includes threezinc-binding domains, a RING, a B-box type 1 and a B-box type 2,and a coiled-coil region. The protein localizes to the cytoplasm.Alternatively spliced transcript variants have been described, buttheir biological validity has not been determined. [provided byRefSeq].
References
McElroy, J.P., et al. Hum. Mol. Genet. 19(15):3080-3088(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Barcellos, L.F., et al. PLoS Genet. 5 (10), E1000696 (2009) :Uchil, P.D., et al. PLoS Pathog. 4 (2), E16 (2008) :Lamesch, P., et al. Genomics 89(3):307-315(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
